Literature DB >> 29377276

A new automated turbidimetric immunoassay for the measurement of canine C-reactive protein.

Matilde Piñeiro1,2, Raquel Pato3, Lourdes Soler4, Raquel Peña3,5, Natalia García4, Carlos Torrente6, Yolanda Saco3, Fermín Lampreave4, Anna Bassols3, Francesca Canalias5.   

Abstract

BACKGROUND: In dogs, as in humans, C-reactive protein (CRP) is a major acute phase protein that is rapidly and prominently increased after exposure to inflammatory stimuli. CRP measurements are used in the diagnosis and monitoring of infectious and inflammatory diseases.
OBJECTIVES: The study aim was to develop and validate a turbidimetric immunoassay for the quantification of canine CRP (cCRP), using canine-specific reagents and standards.
METHODS: A particle-enhanced turbidimetric immunoassay was developed. The assay was set up in a fully automated analyzer, and studies of imprecision, limits of linearity, limits of detection, prozone effects, and interferences were carried out. The new method was compared with 2 other commercially available automated immunoassays for cCRP: one turbidimetric immunoassay (Gentian CRP) and one point-of-care assay based on magnetic permeability (Life Assays CRP).
RESULTS: The within-run and between-day imprecision were <1.7% and 4.2%, respectively. The assay quantified CRP proportionally in an analytic range up to 150 mg/L, with a prozone effect appearing at cCRP concentrations >320 mg/L. No interference from hemoglobin (20 g/L), triglycerides (10 g/L), or bilirubin (150 mg/L) was detected. Good agreement was observed between the results obtained with the new method and the Gentian cCRP turbidimetric immunoassay.
CONCLUSIONS: The new turbidimetric immunoassay (Turbovet canine CRP, Acuvet Biotech) is a rapid, robust, precise, and accurate method for the quantification of cCRP. The method can be easily set up in automated analyzers, providing a suitable tool for routine clinical use.
© 2018 American Society for Veterinary Clinical Pathology.

Entities:  

Keywords:  Acute phase proteins; C-reactive protein; Method comparison

Mesh:

Substances:

Year:  2018        PMID: 29377276     DOI: 10.1111/vcp.12576

Source DB:  PubMed          Journal:  Vet Clin Pathol        ISSN: 0275-6382            Impact factor:   1.180


  21 in total

1.  The Sickness Behavior Inventory-Revised: Sickness behavior and its associations with depression and inflammation in patients with metastatic lung cancer.

Authors:  Daniel C McFarland; Leah E Walsh; Rebecca Saracino; Christian J Nelson; William Breitbart; Barry Rosenfeld
Journal:  Palliat Support Care       Date:  2021-06

2.  Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients.

Authors:  Daniel C McFarland; Devika R Jutagir; Barry Rosenfeld; William Pirl; Andrew H Miller; William Breitbart; Christian Nelson
Journal:  Psychooncology       Date:  2019-05-15       Impact factor: 3.894

3.  Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation.

Authors:  Daniel C McFarland; Devika R Jutagir; Andrew H Miller; William Breitbart; Christian Nelson; Barry Rosenfeld
Journal:  J Natl Compr Canc Netw       Date:  2020-04       Impact factor: 11.908

4.  C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.

Authors:  Daniel C McFarland; Kelly Shaffer; William Breitbart; Barry Rosenfeld; Andrew H Miller
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

5.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

6.  Evaluation of an automated immunoturbidimetric assay for detecting canine C-reactive protein.

Authors:  Michele Berlanda; Carlotta Valente; Federico Bonsembiante; Tamara Badon; Silvia Bedin; Barbara Contiero; Carlo Guglielmini; Helen Poser
Journal:  J Vet Diagn Invest       Date:  2020-09-23       Impact factor: 1.279

7.  Depression and Inflammation in Patients With Lung Cancer: A Comparative Analysis of Acute Phase Reactant Inflammatory Markers.

Authors:  Daniel C McFarland; William Breitbart; Andrew H Miller; Christian Nelson
Journal:  Psychosomatics       Date:  2020-04-02       Impact factor: 2.386

8.  Early childhood adversity in adult patients with metastatic lung cancer: Cross-sectional analysis of symptom burden and inflammation.

Authors:  Daniel C McFarland; Christian Nelson; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2020-08-11       Impact factor: 7.217

9.  Prognostic implications of depression and inflammation in patients with metastatic lung cancer.

Authors:  Daniel C McFarland; Rebecca M Saracino; Andrew H Miller; William Breitbart; Barry Rosenfeld; Christian Nelson
Journal:  Future Oncol       Date:  2020-12-11       Impact factor: 3.404

10.  Neutrophil to Lymphocyte Ratio in Lung Cancer: Implications for Depressive Symptoms and Survival.

Authors:  Daniel C McFarland
Journal:  Clin Oncol Res       Date:  2020-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.